Tennessee, USA-based firm Rare Disease Therapeutics (RDT) has secured a new expanded indication for its antivenom product Anavip (crotalidae immune).
The privately-held company has been granted a broader label for the product, to include treatment of snake bites from rattlesnakes, copperheads, and cottonmouth or water moccasins.
The product was previously indicated for the management of adult and pediatric patients with North American rattlesnake envenomation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze